ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0130

Early Humoral Responses of Hemodialysis Patients After COVID-19 Vaccination with BNT162b2

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Speer, Claudius, University of Heidelberg, Heidelberg, Germany
  • Benning, Louise, University of Heidelberg, Heidelberg, Germany
  • Nusshag, Christian, University of Heidelberg, Heidelberg, Germany
  • Kälble, Florian, University of Heidelberg, Heidelberg, Germany
  • Schnitzler, Paul, University of Heidelberg, Heidelberg, Germany
  • Zeier, Martin G., University of Heidelberg, Heidelberg, Germany
  • Morath, Christian, University of Heidelberg, Heidelberg, Germany
  • Süsal, Caner, University of Heidelberg, Heidelberg, Germany
  • Klein, Katrin, University of Heidelberg, Heidelberg, Germany
Background

Patients receiving hemodialysis are at high risk for both SARS-CoV-2 infection and severe COVID-19. A life-saving vaccine is available, but sensitivity to vaccines is lower in dialysis patients. Little is yet known about antibody response after COVID-19 vaccination in this vulnerable group.

Methods

In this prospective study, we included 22 dialysis patients and 46 healthy controls from Heidelberg University. We measured anti-S1 IgG with a threshold index for detection >1, neutralizing antibodies, and antibodies against different SARS-CoV-2 fragments 17–22 days after the first and 18–22 days after the second dose of BNT162b2.

Results

After the first vaccine dose, 4/22 (18%) dialysis patients compared with 43/46 (93%) healthy controls developed positive anti-S1 IgG, with a median (IQR) anti-S1 IgG index of 0.2 (0.1–0.7) compared with 9 (4–16), respectively. SARS-CoV-2 neutralizing antibodies exceeded the threshold for neutralization in 4/22 (18%) dialysis patients compared with 43/46 (93%) in healthy controls, with a median (IQR) percent inhibition of 11 (3–24) compared with 65 (49–75), respectively. After the second dose, 14/17 (82%) of dialysis patients developed neutralizing antibodies exceeding the threshold for viral neutralization and antibodies against the receptor-binding S1-domain of the spike protein, compared to 46/46 (100%) of healthy controls, respectively. The median (IQR) percent inhibition was 51 (32–86) compared to 98 (97–98) in healthy controls.

Conclusion

Patients receiving long-term hemodialysis show a reduced antibody response to the first and second doses of the mRNA vaccine BNT162b2. The majority (82%) develop neutralizing antibodies after the second dose, but at lower levels than healthy controls.

Figure 1